| Repeated Superselective Intraarterial Cerebral Infusion (SIACI) of Bevacizumab With Temozolomide and Radiation Compared to Temozolomide and Radiation Alone in Newly Diagnosed GBM (NCT05271240) | Northwell Health | 2022-04-27 |
| A Study of SVZ Irradiation With Postoperative Radiotherapy in Patients With GBM. (NCT06092255) | Jiangsu Cancer Institute & Hospital | 2022-03-01 |
| Recurrent GBM Treated With Neurosurgical Resection and IORT Using the Xoft Axxent eBx System and Bevacizumab (NCT04681677) | Xoft, Inc. | 2021-11-02 |
| Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma (NCT05076513) | Nader Sanai | 2021-10-29 |
| Recurrent GBM With Maximal Neurosurgical Removal and Treatment With IORT (NCT04763031) | Parkridge Medical Center | 2021-03-05 |
| Surgical Nivolumab And Ipilimumab For Recurrent GBM (NCT04606316) | Patrick Wen, MD | 2021-02-01 |
| Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma (NCT04528680) | Northwestern University | 2020-10-29 |
| Methylation Patterns of the NUPR1, MGMT, NDRG2, and GLI1 Genes and Their Impact on Therapeutic Outcome of GBM Patients (NCT06538428) | Ain Shams University | 2020-09-01 |
| Infigratinib in Recurrent High-Grade Glioma Patients (NCT04424966) | Nader Sanai | 2020-07-21 |
| LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients (NCT04391595) | Nader Sanai | 2020-07-11 |
| A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors (NCT04478279) | Sapience Therapeutics | 2020-07-01 |
| Laparoscopically Harvested Omental Free Tissue Autograft to Bypass the Blood Brain Barrier (BBB) in Human Recurrent Glioblastoma Multiforme (rGBM) (NCT04222309) | Northwell Health | 2020-01-06 |
| Niraparib/TTFields in GBM (NCT04221503) | Abramson Cancer Center at Penn Medicine | 2019-12-30 |
| Abemaciclib w/Bevacizumab in Recurrent GBM Pts w/Loss of CDKN2A/B or Gain or Amplification of CDK4/6 (NCT04074785) | University of Texas Southwestern Medical Center | 2019-12-13 |
| Evaluate the Efficacy and Safety of ADCV01 As an Add-On Treatment for Primary Glioblastoma Multiforme (GBM) Patients (NCT04115761) | Ever Supreme Bio Technology Co., Ltd. | 2019-06-06 |
| Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma (NCT03782415) | MediciNova | 2018-12-29 |
| Studies of Chlorogenic Acid for Injection for Safety and Efficacy of Grade IV GBM Patients (NCT03758014) | Sichuan J.Z. Bio-chemical Science and Technology Development Co., Ltd | 2018-11-27 |
| To Evaluate the Efficacy and Safety of CAN008 Combined With Re-irradiation (rRT) for Treating Patients With Recurrent Glioblastoma (GBM) (NCT03746288) | CANbridge Life Sciences Ltd. | 2018-11-20 |
| A Phase II/III Study of High-dose, Intermittent Sunitinib in Patients With Recurrent Glioblastoma Multiforme (NCT03025893) | Amsterdam UMC, location VUmc | 2018-08-31 |
| Surgical Tissue Flap to Bypass the Blood Brain Barrier in GBM (NCT03630289) | Northwell Health | 2018-07-27 |
| Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma (NCT03341806) | Icahn School of Medicine at Mount Sinai | 2018-06-13 |
| Ketogenic Diet in Combination With Standard-of-care Radiation and Temozolomide for Patients With Glioblastoma (NCT03451799) | Jethro Hu | 2018-04-13 |
| Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma (NCT03426891) | H. Lee Moffitt Cancer Center and Research Institute | 2018-03-16 |
| Nivolumab, Ipilimumab, and Short-course Radiotherapy in Adults With Newly Diagnosed, MGMT Unmethylated Glioblastoma (NCT03367715) | NYU Langone Health | 2018-02-07 |
| Safety Study of VAL-083 and Radiotherapy in Patients With Newly Diagnosed GBM Having Unmethylated MGMT Expression (NCT03050736) | Kintara Therapeutics, Inc. | 2017-12-17 |
| BrUOG 329 Onivyde & Metronomic Temozolomide in Recurrent Glioblastoma (NCT03119064) | Brown University | 2017-11-30 |
| VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM (NCT03149575) | DelMar Pharmaceuticals, Inc. | 2017-10-27 |
| Study of VAL-083 in Patients With MGMT Unmethylated, Bevacizumab-naive Glioblastoma in the Adjuvant or Recurrent Setting (NCT02717962) | Kintara Therapeutics, Inc. | 2017-01-20 |
| TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma (NCT02663271) | University of Florida | 2016-12-19 |
| A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) (NCT02974738) | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2016-12-07 |
| A Nomogram for Predicting the Diagnosis of Central Malignant Tumors Based on Preoperative Clinical Characteristics and Laboratory Indicators: (NCT06914700) | Guangdong Provincial People's Hospital | 2016-09-01 |
| Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme (NCT02465268) | University of Florida | 2016-08-09 |
| Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma (NCT02861898) | Northwell Health | 2016-06-01 |
| Integrative Analysis of Human Glioblastoma Multiforme (NCT03005132) | Shanghai 10th People's Hospital | 2016-01-01 |
| The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients (NCT02623231) | Tel-Aviv Sourasky Medical Center | 2015-12-01 |
| A Phase 0 Study of AZD1775 in Recurrent GBM Patients (NCT02207010) | St. Joseph's Hospital and Medical Center, Phoenix | 2014-07-01 |
| BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) (NCT01856933) | Heinrich Elinzano, MD | 2013-05-01 |
| A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme (NCT01752491) | Joseph J. Cullen, MD, FACS | 2013-04-01 |
| FET-PET for Evaluation of Response of Recurrent GBM to Avastin (NCT01756352) | Marcelo F. Di Carli, MD, FACC | 2013-02-01 |
| PVSRIPO for Recurrent Glioblastoma (GBM) (NCT01491893) | Istari Oncology, Inc. | 2012-04-25 |
| Safety and Efficacy of Trans Sodium Crocetinate (TSC) With Radiation and Temozolomide in Newly Diagnosed Glioblastoma (NCT01465347) | Diffusion Pharmaceuticals Inc | 2012-02-01 |
| Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma (NCT01478178) | Kintara Therapeutics, Inc. | 2011-10-01 |
| Administration of CMV-Specific Cytotoxic T Cells in Patients With Glioblastoma Multiforme (NCT01205334) | Baylor College of Medicine | 2010-11-01 |
| PF-00299804 in Adult Patients With Relapsed/Recurrent Glioblastoma (NCT01112527) | Massachusetts General Hospital | 2010-04-01 |
| Study of AR-67 in Adult Patients With Recurrence of Glioblastoma Multiforme (GBM) or Gliosarcoma (NCT01124539) | Arno Therapeutics | 2009-12-01 |
| Super-Selective Intraarterial Cerebral Infusion of Cetuximab (Erbitux) for Treatment of Relapsed/Refractory GBM and AA (NCT01238237) | Northwell Health | 2009-12-01 |
| A Study of 131I-TM601 in Adults With Recurrent Malignant Glioma (NCT00683761) | TransMolecular | 2008-08-01 |
| Safety and Dose-Finding Study of TM-601 in Adults With Recurrent Malignant Glioma (NCT00591058) | TransMolecular | 2008-02-01 |
| Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer (NCT00045968) | Northwest Biotherapeutics | 2006-12-01 |
| GW572016 to Treat Recurrent Malignant Brain Tumors (NCT00107003) | National Cancer Institute (NCI) | 2005-03-30 |
| 131-I-TM-601 Study in Adults With Recurrent High-Grade Glioma (NCT00114309) | TransMolecular | 2004-11-01 |
| Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221 (NCT02146066) | Northwest Biotherapeutics | |
| Single Patient Compassionate Use / Expanded Access L-S-Gboxin (Lyophilized Form of S-Gboxin) for the Treatment of Diffuse Midline Glioma (NCT06439849) | Petrov, Andrey | |